Similar articles

• Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis.

  Hirsh J. Hirsh J. Semin Hematol. 1997 Oct;34(4 Suppl 4):20-5. Semin Hematol. 1997. PMID: 9399406 Review. No abstract available.
• A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.

  Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. Simonneau G, et al. N Engl J Med. 1997 Sep 4;337(10):663-9. doi: 10.1056/NEJM199709043371002. N Engl J Med. 1997. PMID: 9278462 Clinical Trial.
• Unfractionated heparin, time for a change?

  Ridgway PF, Crosbie J, Hinedi KA, Ghadban W, Kelly A, O'Donnell R, Hollingsworth J. Ridgway PF, et al. Ir Med J. 1999 Apr;92(3):302-6. Ir Med J. 1999. PMID: 10394757
• The emerging role of low-molecular-weight heparin in cardiovascular medicine.

  Hirsh J, Bates SM. Hirsh J, et al. Prog Cardiovasc Dis. 2000 Jan-Feb;42(4):235-46. doi: 10.1053/pcad.2000.0420235. Prog Cardiovasc Dis. 2000. PMID: 10661777 Review.
• [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].

  Husted SE, Nielsen HK. Husted SE, et al. Ugeskr Laeger. 2010 Oct 18;172(42):2888-91. Ugeskr Laeger. 2010. PMID: 21040659 Review. Danish.